Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Verona Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Ritedose Partners with Verona Pharma To Deliver COPD Drug Ohtuvayre
Details : Verona partnered with Ritedose for the development and manufacturing partner of Ohtuvayre (ensifentrine), a new novel product for Chronic Obstructive Pulmonary Disease.
Brand Name : Ohtuvayre
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Verona Pharma
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?